

Phase 1B Study of Vemurafenib in Combination with the MEK inhibitor, GDC-0973, in Patients with Unresectable or Metastatic *BRAF^{V600}*-Mutated Melanoma (BRIM7)

Rene Gonzalez,¹ Antoni Ribas, ² Adil Daud,³ Anna Pavlick,⁴ Thomas F. Gajewski,⁵ Igor Puzanov,⁶ Melinda S.L. Teng,⁷ Iris T. Chan,⁷ Nicholas Choong,⁷ Grant McArthur⁸

¹University of Colorado Comprehensive Cancer Center, Denver, CO, USA;
²The Jonsson Comprehensive Cancer Center at University of California, Los Angeles, CA, USA;
³Hematology/Oncology Division, University of California, San Francisco, CA, USA;
⁴New York University Medical Center, New York, NY, USA; ⁵University of Chicago, Chicago, USA;
⁶Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; ⁷Genentech, South San Francisco, CA, USA;
⁸Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia





- Consulting, advisory boards for Roche/Genentech and GSK
- Corporate sponsored research for Roche/Genentech and GSK



Acquired resistance to BRAF inhibition

MEK-dependent resistance MEK-independent resistance NRAS mutations **RTK ligand** BRAF^{V600} **BRAF**^{V600} mutation overexpression RTK mutation truncation / amplification **RTK** overexpression vemurafenib PI3K **COT** overexpression **MEK MEK mutations GDC-0973** AKT ERK Cell survival Cell survival


Corcoran RB, et al. Sci Signal 2010 23;3:ra84; Villanueva J et al. Cancer Cell 2010; Nazarian R et al. Nature 2010; Su F et al. Cancer Res 2011; Wagle N et al. J Clin Oncol 2011; Johannessen CM et al. Nature 2010; Poulikakos PI et al. Nature 2011





Combined BRAF & MEK inhibition: Preclinical data & PET scan response

European Society for Medical Oncology

- Preclinical data support combined inhibition of BRAF and MEK:
 - Prevents the emergence of resistance
 - Overcomes acquired resistance







Day 1

Day 14

PET scan response in a patient after progression on vemurafenib and after treatment with vemurafenib + GDC-0973



GDC-0973 & BRIM7 study objectives

European Society for Medical Oncology

GDC-0973*:

- Orally available, potent and highly selective small-molecule inhibitor of both MEK 1 and MEK 2
- GDC-0973 monotherapy Phase I study:
 - 14 day on/14 day off schedule MTD = 100mg
 - 21 day on/7 day off schedule MTD = 60mg
 - Common AEs: diarrhea, rash, edema, fatigue, nausea
 - Encouraging single-agent activity in *BRAF*^{V600} melanoma
 - 7 responders out of 12 melanoma patients
 - 6 responders were BRAF^{V600E} mutation-positive (1 pt unknown mutation status)
 - Median time on GDC-0973 treatment: 9.3 months (range 1.4 23 + months).


BRIM7 Objectives:

- To evaluate the safety and tolerability of vemurafenib + GDC-0973
- To identify the dose-limiting toxicities (DLTs) that determine the maximum tolerated dose (MTD) of vemurafenib + GDC-0973
- To identify a Phase II/III dose and schedule for vemurafenib + GDC-0973

*GDC-0973 is being developed by Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis



BRIM7 study design: Dose-escalation and expansion stages



- **Dose escalation stage:** 10 cohorts, 3–6 patients/cohort
- **Expansion stage:** up to 20 BRAFi-naïve and vemurafenib-progressing patients, respectively



Key inclusion and exclusion criteria

- Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma
- Measurable disease (RECIST version 1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- Adequate hematologic, liver and renal function
- Patients had either:
 - no prior exposure to BRAF inhibitor therapy, OR
 - progressed on vemurafenib immediately prior to enrollment in this study
- Patients were excluded if they had:
 - Ocular pathology or risk factors that predispose to retinal vein occlusion
 - QTc > 450ms
 - Active CNS metastasis. Patients treated with stereotactic RT or surgery are eligible if stable for ≥ 3 weeks




BRIM7 Study: Patient characteristics (6 July 2012)

European Society for Medical Oncology

Treated patients (n=70) Median age, years (range) 57.5 years (19–76) Gender, n (%) Male 49 (70.0) Female 21 (30.0) ECOG performance status, n (%) PS₀ 35 (50.0) **PS**₁ 35 (50.0) Elevated LDH at baseline, n (%) 44 (63.0) Melanoma stage at enrollment, n (%) Unresectable stage IIIc 6 (8.6) Stage IV, M1a 2 (2.9) Stage IV, M1b 10 (14.3) Stage IV, M1c 52 (74.3) Vemurafenib progressors, n (%) 38 (54.3) 3 cycles (1 - 13)Median treatment cycles



BRIM7 Results: Cohort Assignment and Dose-limiting toxicity (6 July 2012)



- As of 6 July 2012, 6 out of 10 dose cohorts have met the protocol-specified criteria to be declared safe (cohorts shown in green in figures below)
- One DLT observed in Cohort 1B: Gr 3 QT interval prolongation, related to vemurafenib

BRIM-7 Results: AEs attributed to either vemurafenib or GDC-0973 in all patients* (6 July 2012)

Most common AEs attributed to either vemurafenib or GDC-0973						
n=70	Grade 3 or 4		Total			
	n	%	n	%		
Total number of patients with AEs	20	28.6	67	95.7		
Non-acneiform rash ^a	5	7.1	37	52.9		
Diarrhea	4	5.7	36	51.4		
Photosensitivity / Sunburn	0	0	22	31.4		
Fatigue	1	1.4	21	30.0		
Nausea	1	1.4	20	28.6		
Selected AEs attributed to either vemurafenib or GDC-0973						
Creatine phosphokinase elevation	3	4.3	14	20.0		
Liver function test elevation ^b	3	4.3	14	20.0		
Arthralgia	1	1.4	9	12.9		
Serous chorioretinopathy ^c	0	0	3	4.3		
Cutaneous squamous cell carcinoma, KA	1	1.4	1	1.4		

*Includes all patients reporting each of AE general terms, even for zero incidence.



^aNon-acneiform rash includes MedDRA terms rash, rash generalised, rash maculo-papular, rash macular, rash papular, rash erythematous, erythema, rash pruritic, dermatitis, skin exfoliation, dermatitis exfoliative, lividity

^bLFT elevation includes MedDRA terms alkaline phosphatase increased, bilirubin increased, hyperbilirubinaemia, AST & ALT increased, transaminases increased, and gamma-glutamyltransferase increased.

^c Serous chorioretinopathy includes MedDRA terms chorioretinal disorder, chorioretinopathy, 1 pt with blurred vision later diagnosed as serous choreoretinopathy.

BRIM-7: AEs leading to dose interruptions, reductions and permanent discontinuations (6 July 2012)

All pts (n=70)	Vemurafenib	GDC-0973	Vem and GDC-0973
Temporary interruption	17 (24.3%)	15 (21.4%)	13 (18.6%)
Dose reduction	3 (4.3%)	2 (2.9%)	2 (2.9%)
Permanent discontinuation due to AE	1 (1.4%)	0 (0%)	0 (0%)

Most common reasons for temporary interruption of vem: Rash 8pts, LFT abnormalities 3pts and arthralgia 3pts Most common reasons for temporary interruption of GDC-0973: Rash 5pts and diarrhea 3pts

Reasons for primary dose reduction interruption of vem: LFT abnormality 1pt, central serous retinopathy 1pt and rash 1pt Reasons for primary dose reduction interruption of GDC-0973: Central serous retinopathy 1pt and rash 1pt


Reason for discontinuation of vemurafenib: QT interval prolongation 1pt



www.esmo2012.org

BRIM7 Results: Change in tumor size from baseline to best response in patients who progressed on prior vemurafenib

Best Tumor Response for Each Patient (Vemurafenib Progressors)



Individual Patients Treated with Vemurafenib and GDC-0973


n=32 evaluable patients

SLD, sum of longest diameters

VIENNA 2012 congress

www.esmo2012.org

BRIM7 Results: Change in tumor size from baseline to best response in <u>BRAFi-naïve patients</u>



Best Tumor Response for Each Patient (BRAFi-naïve)

Individual Patients Treated with Vemurafenib and GDC-0973

n=25 evaluable patients



www.esmo2012.org



BRIM7: Conclusions

- GDC-0973 in combination with vemurafenib can be delivered safely at the respective single-agent MTDs:
 - vemurafenib 960 mg BID, and
 - GDC-0973 60 mg QD 21 days on / 7 days off
- Adverse events were tolerable and manageable
- Preliminary anti-tumor activity in vemurafenib-naïve patients is encouraging
- Phase 3 study of vemurafenib + GDC-0973 is being initiated



Acknowledgements

European Society for Medical Oncology

We thank the patients and their families who participated in this trial.

The following investigators and sponsor members have contributed to the study:

- Karl Lewis, MD
- Omid Hamid, MD
- Theodore Logan, MD
- Lawrence Flaherty, MD
- Study co-ordinators and research nurses
- Genentech/Roche:
 - Hina Maniar (Clinical science);
 - Scott Chandler, Erica Park and Jacob Zeffren (Safety);
 - Luna Musib and WeiJiang Zhang (Pharmacology)